RBAK-RBAKDN: A Promising Drug Target / Biomarker (G100533952)
RBAK-RBAKDN: A Promising Drug Target / Biomarker
RBAK-RBAKDN is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. Its full name is retinal-protein-associated kinase-related B-type DNA-binding protein. It is a potential drug target or biomarker that can be used for the treatment of various diseases, including neurodegenerative disorders, diabetes, and cancer.
The RBAK-RBAKDN Protein
RBAK-RBAKDN is a 21-kDa protein that is expressed in the brain and other tissues of the body. It is characterized by a N-terminal domain that contains a catalytic active site and a C-terminal domain that contains a nuclear localization region. The N-terminal domain contains a short amino acid sequence that is specific to RBAK-RBAKDN and is involved in the protein's nuclear localization. The C-terminal domain contains a long amino acid sequence that is involved in the protein's DNA-binding properties.
RBAK-RBAKDN's DNA-binding Properties
RBAK-RBAKDN is a DNA-binding protein that can interact with specific DNA sequences. Its DNA-binding properties are regulated by various factors, including its phosphorylation state and its presence in the form of a complex with DNA. RBAK-RBAKDN has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases, including neurodegenerative disorders, diabetes, and cancer.
In Neurodegenerative Disorders
RBAK-RBAKDN has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that RBAK-RBAKDN is expressed in the brains of individuals with these disorders and that its levels are decreased in the brains of individuals with these disorders compared to age-matched controls. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of these disorders, including tau and beta-amyloid.
In Diabetes
RBAK-RBAKDN has also been shown to be involved in the development and progression of diabetes. Studies have shown that RBAK-RBAKDN is expressed in the pancreatic cells of individuals with type 1 diabetes and that its levels are decreased in these cells compared to the cells of individuals without diabetes. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of diabetes, including Insulin-like growth factor 1 (IGF-1) and GLUT1.
In Cancer
RBAK-RBAKDN has also been shown to be involved in the development and progression of cancer. Studies have shown that RBAK-RBAKDN is expressed in various tissues of individuals with cancer and that its levels are often decreased in these tissues compared to the surrounding tissues. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of cancer, including p53 and NF-kappa-B.
Potential Therapeutic Applications
Given RBAK-RBAKDN's involvement in the regulation of gene expression and its potential involvement in the development and progression of various diseases, there is a high demand for compounds that can inhibit its activity. Currently, there are several RBAK-RBAKDN inhibitors that are being developed as potential therapeutic compounds for the treatment of neurodegenerative disorders, diabetes, and cancer. These compounds can include small molecules, peptides, and proteins.
Conclusion
RBAK-RBAKDN is a protein that is expressed in various tissues
Protein Name: RBAK-RBAKDN Readthrough
The "RBAK-RBAKDN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBAK-RBAKDN comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1
